Home/Filings/4/0001209191-23-022649
4//SEC Filing

Treco Douglas A 4

Accession 0001209191-23-022649

CIK 0001693011other

Filed

Apr 3, 8:00 PM ET

Accepted

Apr 4, 4:05 PM ET

Size

12.7 KB

Accession

0001209191-23-022649

Insider Transaction Report

Form 4
Period: 2023-04-01
Treco Douglas A
DirectorCEO & Chairman
Transactions
  • Award

    Restricted stock units

    2023-04-01+100,000100,000 total
    Common stock (100,000 underlying)
  • Award

    Stock option (right to buy)

    2023-04-01+800,000800,000 total
    Exercise: $5.73Exp: 2033-03-31Common stock (800,000 underlying)
Footnotes (3)
  • [F1]The exercise price represents the closing price of the Issuer's common stock on March 31, 2023.
  • [F2]The option was granted on April 1, 2023 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
  • [F3]The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date.

Issuer

Inozyme Pharma, Inc.

CIK 0001693011

Entity typeother

Related Parties

1
  • filerCIK 0001688192

Filing Metadata

Form type
4
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 4:05 PM ET
Size
12.7 KB